3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) recently received a patent from the Canadian Intellectual Property office, which protects the company’s IP in the area of cognitive diseases in general and Alzheimer’s disease (AD) in particular.
In addition, the U.S. Patent and Trademark Office recently issued a patent that protects 3DS’ IP related to the hematological disorders tests currently in development. It provides further protection for the company’s proof-of-principle test, Telo-HL, a predictive test performed on diagnostic lymph node specimens.
The test is intended to provide clinicians with the first biomarker capable of identifying the 15% to 20% of Hodgkin’s lymphoma patients who will fail standard ABVD chemotherapy, and who should immediately be considered for more advanced treatment or inclusion into clinical trials with an emerging immunotherapy. It also protects the company’s test development in the area of multiple myeloma.
The data related to the latest patent for AD was collected from two independent and published clinical studies that included 170 patients from all stages of AD. The data positions 3DS’ Telo-AD test as potentially having clinical utility in the screening, diagnosis and staging of AD as well as a possible role in monitoring disease progression in patients with AD.
